The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity

Alexander M. Efanov, Sergei V. Zaitsev, Hans Juergen Mest, Achim Raap, Ioulia B. Appelskog, Olof Larsson, Per Olof Berggren, Suad Efendic

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The insulinotropic activity of the novel imidazoline compound BL11282 was investigated. Intravenous administration of BL11282 (0.3 mg · kg-1 · min-1) to anesthetized rats did not change blood glucose and insulin levels under basal conditions, but produced a higher increase in blood insulin levels and a faster glucose removal from the blood after glucose infusion. Similarly, in isolated Wistar rat pancreatic islets, 0.1-100 μmol/l BL11282 potently stimulated glucose-induced insulin secretion but did not modulate basal insulin secretion. Unlike previously described imidazolines, BL11282 did not block ATP-dependent K+ channels. Furthermore, the compound stimulated insulin secretion in islets depolarized with high concentrations of KCl or permeabilized with electric shock. Insulinotropic activity of BL11282 was dependent on activity of protein kinases A and C. In pancreatic islets from spontaneously diabetic GK rats, the imidazoline compound restored the impaired insulin response to glucose. In conclusion, the imidazoline BL11282 constitutes a new class of insulinotropic compounds that exerts an exclusive glucose-dependent insulinotropic activity in pancreatic islets by stimulating insulin exocytosis.

Original languageEnglish
Pages (from-to)797-802
Number of pages6
JournalDiabetes
Volume50
Issue number4
StatePublished - Apr 7 2001
Externally publishedYes

Fingerprint

BL 11282
Imidazolines
KATP Channels
Insulin
Glucose
Islets of Langerhans
Blood Glucose
Exocytosis
Cyclic AMP-Dependent Protein Kinases
Intravenous Administration
Protein Kinase C
Wistar Rats

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Efanov, A. M., Zaitsev, S. V., Mest, H. J., Raap, A., Appelskog, I. B., Larsson, O., ... Efendic, S. (2001). The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. Diabetes, 50(4), 797-802.

The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. / Efanov, Alexander M.; Zaitsev, Sergei V.; Mest, Hans Juergen; Raap, Achim; Appelskog, Ioulia B.; Larsson, Olof; Berggren, Per Olof; Efendic, Suad.

In: Diabetes, Vol. 50, No. 4, 07.04.2001, p. 797-802.

Research output: Contribution to journalArticle

Efanov, AM, Zaitsev, SV, Mest, HJ, Raap, A, Appelskog, IB, Larsson, O, Berggren, PO & Efendic, S 2001, 'The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity', Diabetes, vol. 50, no. 4, pp. 797-802.
Efanov, Alexander M. ; Zaitsev, Sergei V. ; Mest, Hans Juergen ; Raap, Achim ; Appelskog, Ioulia B. ; Larsson, Olof ; Berggren, Per Olof ; Efendic, Suad. / The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. In: Diabetes. 2001 ; Vol. 50, No. 4. pp. 797-802.
@article{bed7ad4afd7746f2b96616c20c47a89f,
title = "The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity",
abstract = "The insulinotropic activity of the novel imidazoline compound BL11282 was investigated. Intravenous administration of BL11282 (0.3 mg · kg-1 · min-1) to anesthetized rats did not change blood glucose and insulin levels under basal conditions, but produced a higher increase in blood insulin levels and a faster glucose removal from the blood after glucose infusion. Similarly, in isolated Wistar rat pancreatic islets, 0.1-100 μmol/l BL11282 potently stimulated glucose-induced insulin secretion but did not modulate basal insulin secretion. Unlike previously described imidazolines, BL11282 did not block ATP-dependent K+ channels. Furthermore, the compound stimulated insulin secretion in islets depolarized with high concentrations of KCl or permeabilized with electric shock. Insulinotropic activity of BL11282 was dependent on activity of protein kinases A and C. In pancreatic islets from spontaneously diabetic GK rats, the imidazoline compound restored the impaired insulin response to glucose. In conclusion, the imidazoline BL11282 constitutes a new class of insulinotropic compounds that exerts an exclusive glucose-dependent insulinotropic activity in pancreatic islets by stimulating insulin exocytosis.",
author = "Efanov, {Alexander M.} and Zaitsev, {Sergei V.} and Mest, {Hans Juergen} and Achim Raap and Appelskog, {Ioulia B.} and Olof Larsson and Berggren, {Per Olof} and Suad Efendic",
year = "2001",
month = "4",
day = "7",
language = "English",
volume = "50",
pages = "797--802",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity

AU - Efanov, Alexander M.

AU - Zaitsev, Sergei V.

AU - Mest, Hans Juergen

AU - Raap, Achim

AU - Appelskog, Ioulia B.

AU - Larsson, Olof

AU - Berggren, Per Olof

AU - Efendic, Suad

PY - 2001/4/7

Y1 - 2001/4/7

N2 - The insulinotropic activity of the novel imidazoline compound BL11282 was investigated. Intravenous administration of BL11282 (0.3 mg · kg-1 · min-1) to anesthetized rats did not change blood glucose and insulin levels under basal conditions, but produced a higher increase in blood insulin levels and a faster glucose removal from the blood after glucose infusion. Similarly, in isolated Wistar rat pancreatic islets, 0.1-100 μmol/l BL11282 potently stimulated glucose-induced insulin secretion but did not modulate basal insulin secretion. Unlike previously described imidazolines, BL11282 did not block ATP-dependent K+ channels. Furthermore, the compound stimulated insulin secretion in islets depolarized with high concentrations of KCl or permeabilized with electric shock. Insulinotropic activity of BL11282 was dependent on activity of protein kinases A and C. In pancreatic islets from spontaneously diabetic GK rats, the imidazoline compound restored the impaired insulin response to glucose. In conclusion, the imidazoline BL11282 constitutes a new class of insulinotropic compounds that exerts an exclusive glucose-dependent insulinotropic activity in pancreatic islets by stimulating insulin exocytosis.

AB - The insulinotropic activity of the novel imidazoline compound BL11282 was investigated. Intravenous administration of BL11282 (0.3 mg · kg-1 · min-1) to anesthetized rats did not change blood glucose and insulin levels under basal conditions, but produced a higher increase in blood insulin levels and a faster glucose removal from the blood after glucose infusion. Similarly, in isolated Wistar rat pancreatic islets, 0.1-100 μmol/l BL11282 potently stimulated glucose-induced insulin secretion but did not modulate basal insulin secretion. Unlike previously described imidazolines, BL11282 did not block ATP-dependent K+ channels. Furthermore, the compound stimulated insulin secretion in islets depolarized with high concentrations of KCl or permeabilized with electric shock. Insulinotropic activity of BL11282 was dependent on activity of protein kinases A and C. In pancreatic islets from spontaneously diabetic GK rats, the imidazoline compound restored the impaired insulin response to glucose. In conclusion, the imidazoline BL11282 constitutes a new class of insulinotropic compounds that exerts an exclusive glucose-dependent insulinotropic activity in pancreatic islets by stimulating insulin exocytosis.

UR - http://www.scopus.com/inward/record.url?scp=0035086032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035086032&partnerID=8YFLogxK

M3 - Article

C2 - 11289044

AN - SCOPUS:0035086032

VL - 50

SP - 797

EP - 802

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -